AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28056704 — intervention group
Group type: EXPERIMENTAL
Intervention: OPFAϖ‐3
Number of subjects: 60
Study 28056704 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 26669965 — intervention group
Group type: EXPERIMENTAL
Intervention: Dianatal obstetric gel
Number of subjects: 200
Study 26669965 — intervention group
Group type: COMPARATOR
Intervention: Control (labor management without obstetric gel)
Number of subjects: 200
Study 24412138 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate characteristics index displayed to clinicians
Number of subjects: 274
Study 24412138 — intervention group
Group type: COMPARATOR
Intervention: Conventional monitoring (heart rate characteristics index not displayed to clinicians)
Number of subjects: 274
Study 22558691 — intervention group
Group type: EXPERIMENTAL
Intervention: lavender oil
Number of subjects: 115
Study 22558691 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 115
Study 20233524 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic syndrome prevalence
Number of subjects: 3785
Study 20233524 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for metabolic syndrome
Number of subjects: 3785
Study 17932127 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 1 g stat.
Number of subjects: 212
Study 17932127 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline for 9 days
Number of subjects: 212
Study 17932127 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended azithromycin (500 mg on day 1 followed by 250 mg daily for 4 days)
Number of subjects: 212
Study 17932127 — intervention group
Group type: COMPARATOR
Intervention: Extended doxycycline treatment
Number of subjects: 212
Study 15965438 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg
Number of subjects: 59
Study 15965438 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 11802751 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil therapy
Number of subjects: 0
Study 10717778 — intervention group
Group type: EXPERIMENTAL
Intervention: EE/GSD
Number of subjects: 1476
Study 10717778 — intervention group
Group type: COMPARATOR
Intervention: EE/DSG
Number of subjects: 1476
Study 10717778 — intervention group
Group type: EXPERIMENTAL
Intervention: Both preparations
Number of subjects: 1476
Study 7741777 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release propafenone 2 x 225 mg
Number of subjects: 24
Study 7741777 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release propafenone 2 x 325 mg
Number of subjects: 24
Study 7741777 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release propafenone 2 x 425 mg
Number of subjects: 24
Study 7741777 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of slow-release propafenone
Number of subjects: 24
Study 7741777 — intervention group
Group type: EXPERIMENTAL
Intervention: R-form of propafenone
Number of subjects: 24
Study 1784666 — intervention group
Group type: EXPERIMENTAL
Intervention: Humorous treatment (humor condition)
Number of subjects: 31
Study 1784666 — intervention group
Group type: COMPARATOR
Intervention: Nonhumorous condition (control)
Number of subjects: 31
Study 1784666 — intervention group
Group type: EXPERIMENTAL
Intervention: Humorous stimuli
Number of subjects: 31
Study 1784666 — intervention group
Group type: COMPARATOR
Intervention: Nonhumorous stimuli
Number of subjects: 31
Study 6294794 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime
Number of subjects: 656
Study 30998059 — intervention group
Group type: EXPERIMENTAL
Intervention: Online expressive writing intervention
Number of subjects: 508
Study 30998059 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive writing intervention
Number of subjects: 508
Study 29846832 — intervention group
Group type: EXPERIMENTAL
Intervention: Helium-neon laser therapy (HNLT) and conventional therapy
Number of subjects: 65
Study 29846832 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrared laser therapy (ILT) and conventional therapy
Number of subjects: 65
Study 26824517 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance exercise (PRE) with 0.5 kg dumbbell, performed twice a day for 8 weeks after complex decongestive physiotherapy
Number of subjects: 32
Study 26824517 — intervention group
Group type: COMPARATOR
Intervention: Non-progressive resistance exercise (non-PRE) group
Number of subjects: 32
Study 24916467 — intervention group
Group type: EXPERIMENTAL
Intervention: EVLTAP (endovenous laser therapy with ambulatory phlebectomy)
Number of subjects: 50
Study 24916467 — intervention group
Group type: COMPARATOR
Intervention: EVLA alone with sequential phlebectomy
Number of subjects: 50
Study 22402727 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct application of vibratory stimuli
Number of subjects: 36
Study 22402727 — intervention group
Group type: COMPARATOR
Intervention: Stretch group
Number of subjects: 36
Study 22402727 — intervention group
Group type: COMPARATOR
Intervention: Rest group
Number of subjects: 36
Study 19327167 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine
Number of subjects: 158
Study 19327167 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine
Number of subjects: 158
Study 19327167 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 158
Study 17767943 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictable condition (color change at a fixed time)
Number of subjects: 0
Study 17767943 — intervention group
Group type: COMPARATOR
Intervention: No-change condition (color does not change)
Number of subjects: 0
Study 17767943 — intervention group
Group type: EXPERIMENTAL
Intervention: Unpredictable condition (color change at random times)
Number of subjects: 0
Study 15143446 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin beta
Number of subjects: 157
Study 15143446 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157
Study 11262534 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-dimensional echocardiography (2-D echo) using apical four-chamber (4C) and two-chamber (2C) views
Number of subjects: 63
Study 11262534 — intervention group
Group type: EXPERIMENTAL
Intervention: Area-length 2-D echo
Number of subjects: 63
Study 11262534 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyeball cineangiography
Number of subjects: 63
Study 11262534 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyeball 2-D echo (method of discs)
Number of subjects: 63
Study 11262534 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyeball 2-D echo (area-length)
Number of subjects: 63
Study 9704764 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly developed health-related quality-of-life measure
Number of subjects: 137
Study 7986236 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba special extract LI 1370 (Kaveri forte) 150 mg daily
Number of subjects: 11
Study 7986236 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 7986236 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba special extract LI 1370 (Kaveri forte)
Number of subjects: 11
Study 2919733 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (50 mg every 6 hours for 72 hours)
Number of subjects: 40
Study 2919733 — intervention group
Group type: COMPARATOR
Intervention: No ranitidine (control group)
Number of subjects: 40
Study 2919733 — intervention group
Group type: COMPARATOR
Intervention: No ranitidine (nonoperative control group)
Number of subjects: 40
Study 31243685 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 μg chromium
Number of subjects: 64
Study 31243685 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 30335211 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT‐ACT intervention
Number of subjects: 28
Study 30335211 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 28
Study 28213592 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 weeks of supervised exercise training
Number of subjects: 142
Study 28213592 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 142
Study 25789270 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine sulfate 2% (10 ml every 3 hours, six times a day for 6 days)
Number of subjects: 30
Study 25789270 — intervention group
Group type: COMPARATOR
Intervention: Magic mouthwash (10 ml every 3 hours, six times a day for 6 days)
Number of subjects: 30
Study 24165976 — intervention group
Group type: EXPERIMENTAL
Intervention: Fedratinib (10-680 mg)
Number of subjects: 0
Study 24165976 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22023525 — intervention group
Group type: EXPERIMENTAL
Intervention: ATG 4.5 mg/kg
Number of subjects: 20
Study 22023525 — intervention group
Group type: COMPARATOR
Intervention: ATG 7.5 mg/kg
Number of subjects: 20
Study 19954486 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant activated factor VII (rFVIIa)
Number of subjects: 117
Study 17299112 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 IU/d natural vitamin E for 3 months, increased to 1200 IU/d for a further 3 months
Number of subjects: 80
Study 17299112 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 15631129 — intervention group
Group type: EXPERIMENTAL
Intervention: Visualization methods that showed the sign of vectors within the vector field
Number of subjects: 0
Study 15631129 — intervention group
Group type: EXPERIMENTAL
Intervention: Visualization methods that visually represented integral curves
Number of subjects: 0
Study 15631129 — intervention group
Group type: EXPERIMENTAL
Intervention: Visualization methods that visually represented the locations of critical points
Number of subjects: 0
Study 15631129 — intervention group
Group type: COMPARATOR
Intervention: Expert user performance
Number of subjects: 0
Study 12081335 — intervention group
Group type: EXPERIMENTAL
Intervention: Medizip Surgical Zipper technique
Number of subjects: 50
Study 12081335 — intervention group
Group type: COMPARATOR
Intervention: Conventional (needle and thread) control group
Number of subjects: 50
Study 9607385 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan 50 mg
Number of subjects: 889
Study 9607385 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan 100 mg
Number of subjects: 889
Study 9607385 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan 200 mg
Number of subjects: 889
Study 9607385 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan 300 mg
Number of subjects: 889
Study 9607385 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan (all doses > or = 50 mg)
Number of subjects: 889
Study 9607385 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) 12.5 mg added to irbesartan
Number of subjects: 889
Study 9607385 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 889
Study 7617573 — intervention group
Group type: EXPERIMENTAL
Intervention: Training with individual feedback
Number of subjects: 35
Study 7617573 — intervention group
Group type: EXPERIMENTAL
Intervention: Training without feedback
Number of subjects: 35
Study 7617573 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 35
Study 1369847 — intervention group
Group type: EXPERIMENTAL
Intervention: Trochanteric osteotomy performed in 79 hips (11%) of 68 patients
Number of subjects: 594
Study 1369847 — intervention group
Group type: EXPERIMENTAL
Intervention: Trochanter reattached by Charnley, Coventry or Amstutz method in 73 hips
Number of subjects: 594
Study 352788 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (40 mg per day)
Number of subjects: 55
Study 352788 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 55
Study 30993836 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 81-8973 low-dose prophylaxis (20-30 IU/kg twice-weekly)
Number of subjects: 23
Study 30993836 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 81-8973 high-dose prophylaxis (30-40 IU/kg 3 times weekly)
Number of subjects: 23
Study 30993836 — intervention group
Group type: COMPARATOR
Intervention: On-demand treatment
Number of subjects: 23
Study 30993836 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 81-8973 prophylaxis
Number of subjects: 23
Study 28255768 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol (400 mcg)
Number of subjects: 120
Study 28255768 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (400 mcg)
Number of subjects: 120
Study 28255768 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol (400 mcg)
Number of subjects: 120
Study 28255768 — intervention group
Group type: COMPARATOR
Intervention: Control (not applicable)
Number of subjects: 120
Study 25930038 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care
Number of subjects: 139
Study 25930038 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 139
Study 24081373 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 15 mg once daily
Number of subjects: 60
Study 24081373 — intervention group
Group type: COMPARATOR
Intervention: Dabigatran 110 mg twice daily
Number of subjects: 60
Study 24081373 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 60
Study 24081373 — intervention group
Group type: COMPARATOR
Intervention: Dabigatran
Number of subjects: 60
Study 21529210 — intervention group
Group type: EXPERIMENTAL
Intervention: Carprofen
Number of subjects: 68
Study 21529210 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 19095991 — intervention group
Group type: EXPERIMENTAL
Intervention: ON antithrombotics
Number of subjects: 568
Study 19095991 — intervention group
Group type: COMPARATOR
Intervention: OFF antithrombotics
Number of subjects: 568
Study 17065971 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 50
Study 17065971 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 15513569 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapleural streptokinase
Number of subjects: 40
Study 15513569 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 40
Study 10420862 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-hour case-based educational session on clinical practice guidelines (CPGs) for depression and access to a psychiatrist for consultation
Number of subjects: 42
Study 10420862 — intervention group
Group type: COMPARATOR
Intervention: Receipt of CPGs without educational session or access to the psychiatrist
Number of subjects: 42
Study 10420862 — intervention group
Group type: EXPERIMENTAL
Intervention: Consultation with psychiatrist
Number of subjects: 42
Study 10420862 — intervention group
Group type: COMPARATOR
Intervention: No consultation with psychiatrist
Number of subjects: 42
Study 10420862 — intervention group
Group type: EXPERIMENTAL
Intervention: Physicians' ratings of depression severity before treatment and at 6 months
Number of subjects: 42
Study 7579485 — intervention group
Group type: EXPERIMENTAL
Intervention: rh GM-CSF (5 micrograms/kg/d for at least ten days)
Number of subjects: 11
Study 2317420 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% plain bupivacaine 4 ml at the L2‐3 spinal interspace (n = 20)
Number of subjects: 40
Study 2317420 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% plain bupivacaine 4 ml at the L4‐5 spinal interspace (n = 20)
Number of subjects: 40
Study 7441484 — intervention group
Group type: EXPERIMENTAL
Intervention: Superimposed presentation of images
Number of subjects: 43
Study 7441484 — intervention group
Group type: COMPARATOR
Intervention: Separated presentation of images
Number of subjects: 43
Study 30289872 — intervention group
Group type: EXPERIMENTAL
Intervention: High Frequency (HF) resistance training (5 times per week)
Number of subjects: 20
Study 30289872 — intervention group
Group type: COMPARATOR
Intervention: Low Frequency (LF) resistance training (2 or 3 times per week)
Number of subjects: 20
Study 30289872 — intervention group
Group type: EXPERIMENTAL
Intervention: High Frequency (HF) resistance training
Number of subjects: 20
Study 30289872 — intervention group
Group type: COMPARATOR
Intervention: Low Frequency (LF) resistance training
Number of subjects: 20
Study 28107643 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 185
Study 28107643 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 185
Study 24286968 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine-containing cough syrups (CCS) users
Number of subjects: 30
Study 24286968 — intervention group
Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 30
Study 23072247 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based intervention targeting parents with general information about nutrition and exercise recommendations through a website and group intervention
Number of subjects: 240
Study 23072247 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based intervention targeting parents
Number of subjects: 240
Study 20686477 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban 2.5 mg twice-daily (b.i.d.)
Number of subjects: 0
Study 20686477 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin 30 mg b.i.d.
Number of subjects: 0
Study 20686477 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 0
Study 20686477 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in daily steady-state AUC(ss) of 1 microg x h/ml
Number of subjects: 0
Study 17715838 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (ALN) 70 mg once weekly
Number of subjects: 335
Study 17715838 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 335
Study 15033968 — intervention group
Group type: EXPERIMENTAL
Intervention: LHTL (live high, train low)
Number of subjects: 13
Study 15033968 — intervention group
Group type: COMPARATOR
Intervention: Control (Con)
Number of subjects: 13
Study 15033968 — intervention group
Group type: EXPERIMENTAL
Intervention: LHTL
Number of subjects: 13
Study 15033968 — intervention group
Group type: COMPARATOR
Intervention: LHTL and Control (Con)
Number of subjects: 13
Study 12079251 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention (Life Skills Training and Strengthening Families Program)
Number of subjects: 36
Study 12079251 — intervention group
Group type: EXPERIMENTAL
Intervention: LST only
Number of subjects: 36
Study 12079251 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 36
Study 10449212 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate aerosol (ISA) 2.5 mg
Number of subjects: 60
Study 10449212 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine 10 mg
Number of subjects: 60
Study 7789487 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 ppm NO2
Number of subjects: 20
Study 7789487 — intervention group
Group type: COMPARATOR
Intervention: Filtered air
Number of subjects: 20
Study 2169714 — intervention group
Group type: EXPERIMENTAL
Intervention: nedocromil sodium 1% nasal solution (Tilarin, QID, Fisons plc)
Number of subjects: 177
Study 2169714 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 177
Study 7449793 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral calcium carbonate
Number of subjects: 50
Study 7449793 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 30347019 — intervention group
Group type: EXPERIMENTAL
Intervention: Alisertib plus paclitaxel
Number of subjects: 191
Study 30347019 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel
Number of subjects: 191
Study 28341120 — intervention group
Group type: EXPERIMENTAL
Intervention: Voice therapy
Number of subjects: 20
Study 28341120 — intervention group
Group type: COMPARATOR
Intervention: Thyroplasty type I and type IV
Number of subjects: 20
Study 26217533 — intervention group
Group type: EXPERIMENTAL
Intervention: Investment based intervention (patients rate and describe their investment before surgery and at 3 and 6 months post-surgery)
Number of subjects: 0
Study 26217533 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 0
Study 26217533 — intervention group
Group type: EXPERIMENTAL
Intervention: Investment based intervention
Number of subjects: 0
Study 26217533 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 23872464 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg APD421
Number of subjects: 215
Study 23872464 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg APD421
Number of subjects: 215
Study 23872464 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg APD421
Number of subjects: 215
Study 23872464 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 215
Study 21734596 — intervention group
Group type: EXPERIMENTAL
Intervention: 3,4-diaminopyridine (3,4-DAP) 10 mg
Number of subjects: 8
Study 21734596 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-aminopyridine (4-AP) 10 mg
Number of subjects: 8
Study 20180679 — intervention group
Group type: EXPERIMENTAL
Intervention: N-of-1 designs for the intervention group
Number of subjects: 0
Study 20180679 — intervention group
Group type: EXPERIMENTAL
Intervention: Small sample prevention study methodology
Number of subjects: 0
Study 17722827 — intervention group
Group type: EXPERIMENTAL
Intervention: Needling acupoints at the same nervous segment
Number of subjects: 116
Study 17722827 — intervention group
Group type: COMPARATOR
Intervention: Routine acupoint selection
Number of subjects: 116
Study 16169160 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 3200 mg (1600 mg bid)
Number of subjects: 129
Study 16169160 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study 15475040 — intervention group
Group type: EXPERIMENTAL
Intervention: Health plan‐based lifestyle intervention focusing on diet (high calcium foods, fruits, and vegetables) and physical activity (high impact and spinal motion)
Number of subjects: 228
Study 11053699 — intervention group
Group type: EXPERIMENTAL
Intervention: Grafted LIMA
Number of subjects: 29
Study 11053699 — intervention group
Group type: COMPARATOR
Intervention: Ungrafted RIMA (Control)
Number of subjects: 29
Study 8852410 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 micrograms antigen load (group A)
Number of subjects: 507
Study 8852410 — intervention group
Group type: COMPARATOR
Intervention: 10 micrograms antigen load (group B)
Number of subjects: 507
Study 1800180 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical cysteamine 0.2% six times a day
Number of subjects: 5